Equitable Trust’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $637K | Buy |
13,295
+163
| +1% | +$7K | 0.03% | 289 |
|
|
2026
Q1 | $483K | Sell |
13,132
-34,178
| -72% | -$1.62M | 0.02% | 329 |
|
|
2025
Q4 | $2.41M | Sell |
47,310
-793
| -2% | -$40.6K | 0.11% | 145 |
|
|
2025
Q3 | $2.67M | Sell |
48,103
-982
| -2% | -$57.5K | 0.12% | 136 |
|
|
2025
Q2 | $3.39M | Sell |
49,085
-18,042
| -27% | -$1.23M | 0.17% | 110 |
|
|
2025
Q1 | $4.66M | Sell |
67,127
-15,504
| -19% | -$1.28M | 0.26% | 75 |
|
|
2024
Q4 | $7.11M | Sell |
82,631
-2,339
| -3% | -$253K | 0.4% | 44 |
|
|
2024
Q3 | $10.1M | Sell |
84,970
-1,108
| -1% | -$148K | 0.65% | 33 |
|
|
2024
Q2 | $12.3M | Buy |
86,078
+2,588
| +3% | +$343K | 0.85% | 27 |
|
|
2024
Q1 | $10.7M | Sell |
83,490
-1,244
| -1% | -$148K | 0.74% | 30 |
|
|
2023
Q4 | $8.77M | Sell |
84,734
-2,933
| -3% | -$290K | 0.66% | 32 |
|
|
2023
Q3 | $7.97M | Buy |
87,667
+10,027
| +13% | +$883K | 0.66% | 31 |
|
|
2023
Q2 | $6.28M | Sell |
77,640
-668
| -0.9% | -$54.6K | 0.48% | 40 |
|
|
2023
Q1 | $6.23M | Sell |
78,308
-7,880
| -9% | -$559K | 0.49% | 38 |
|
|
2022
Q4 | $5.83M | Sell |
86,188
-9,212
| -10% | -$540K | 0.46% | 44 |
|
|
2022
Q3 | $4.75M | Sell |
95,400
-11,244
| -11% | -$602K | 0.4% | 57 |
|
|
2022
Q2 | $5.94M | Buy |
106,644
+26,236
| +33% | +$1.46M | 0.44% | 52 |
|
|
2022
Q1 | $4.46M | Buy |
80,408
+69,356
| +628% | +$3.56M | 0.29% | 81 |
|
|
2021
Q4 | $619K | Hold |
11,052
| – | – | 0.04% | 222 |
|
|
2021
Q3 | $530K | Sell |
11,052
-16
| -0.1% | -$774 | 0.03% | 236 |
|
|
2021
Q2 | $464K | Buy |
11,068
+168
| +2% | +$6.51K | 0.03% | 257 |
|
|
2021
Q1 | $367K | Hold |
10,900
| – | – | 0.03% | 278 |
|
|
2020
Q4 | $381K | Hold |
10,900
| – | – | 0.03% | 268 |
|
|
2020
Q3 | $378K | Hold |
10,900
| – | – | 0.03% | 258 |
|
|
2020
Q2 | $357K | Hold |
10,900
| – | – | 0.03% | 249 |
|
|
2020
Q1 | $328K | Sell |
10,900
-2,198
| -17% | -$65.4K | 0.04% | 245 |
|
|
2019
Q4 | $379K | Buy |
13,098
+58
| +0.4% | +$1.61K | 0.04% | 222 |
|
|
2019
Q3 | $337K | Hold |
13,040
| – | – | 0.04% | 226 |
|
|
2019
Q2 | $333K | Buy |
13,040
+30
| +0.2% | +$741 | 0.04% | 228 |
|
|
2019
Q1 | $340K | Buy |
13,010
+292
| +2% | +$7.18K | 0.04% | 226 |
|
|
2018
Q4 | $293K | Buy |
12,718
+1,326
| +12% | +$29.5K | 0.04% | 226 |
|
|
2018
Q3 | $269K | Sell |
11,392
-102
| -0.9% | -$2.49K | 0.03% | 258 |
|
|
2018
Q2 | $265K | Buy |
+11,494
| New | +$273K | 0.03% | 232 |
|
Other funds holding NVO
F
Equitable Trust's NVO Position: Q2 2026 in Review
Equitable Trust increased its Novo Nordisk (NVO) stake by 1.2% in Q2 2026, buying an estimated $7K and bringing the position to 13,295 shares worth $637K. The position accounts for 0.03% of the portfolio, ranked #289.
Equitable Trust first reported a position in NVO in Q2 2018 and has held it in 33 quarters since. The position peaked at $12.3M in Q2 2024. 1,352 funds tracked by Wall St. Rank hold NVO as of Q2 2026.
- Equitable Trust held 13,295 shares of Novo Nordisk worth $637K as of Q2 2026.
- Equitable Trust bought 163 Novo Nordisk shares in Q2 2026, an estimated $7K.
- Novo Nordisk made up 0.03% of Equitable Trust's portfolio in Q2 2026, its #289 holding.
- Equitable Trust first reported a position in Novo Nordisk in Q2 2018 and has held it in 33 quarters since.
- Equitable Trust's Novo Nordisk position peaked at $12.3M in Q2 2024.
- 1,352 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.
Based on Equitable Trust's 13F filing for Q2 2026, filed 23 Jul 2026.